In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

This is a very complex question that is common among our thoracic tumor board discussions. I'll answer the latter question first. In this case, I would not offer consolidative durvalumab.

There are data that immune checkpoint inhibitors (ICIs) have minimal to no benefit in the metastatic setting base...

While we await LAURA results, I wanted to point out this recent multi-institutional retrospective analysis by Nassar et al., PMID 38278303. This analysis of 136 concurrent chemo-RT patients with stage III NSCLC suggests longer PFS in those receiving consolidative osimertinib compared to durvalumab o...

I thoroughly enjoyed the above discussion points! One more obvious, but important point that I will add is that all patients eventually progress while on EGFR TKIs. These are not curative therapies. Patients who have EGFR-mutated Stages I-III, and even the oligometastatic Stage IV NSCLC, are potenti...

There have been multiple answers in regards to the role of consolidative osimeritinib as per above which, I think some shared decision-making and feasibility of approval is not unreasonable as above until we have LAURA results.

In regards to the first question about considering induction osimeritinib...